Gaurav Aggarwal Net Worth

The estimated Net Worth of Gaurav Aggarwal is at least $150 Milione dollars as of 31 January 2022. Gaurav Aggarwal owns over 800,000 units of Sierra Oncology Inc stock worth over $150,444,556 and over the last 9 years he sold SRRA stock worth over $0. In addition, he makes $0 as Independent Director at Sierra Oncology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gaurav Aggarwal SRRA stock SEC Form 4 insiders trading

Gaurav has made over 2 trades of the Sierra Oncology Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 800,000 units of SRRA stock worth $21,600,000 on 31 January 2022.

The largest trade he's ever made was buying 800,000 units of Sierra Oncology Inc stock on 31 January 2022 worth over $21,600,000. On average, Gaurav trades about 62,308 units every 170 days since 2015. As of 31 January 2022 he still owns at least 2,735,853 units of Sierra Oncology Inc stock.

You can see the complete history of Gaurav Aggarwal stock trades at the bottom of the page.

Gaurav Aggarwal biography

Dr. Gaurav Aggarwal M.D. serves as Independent Director of the Company. Dr. Aggarwal has served as a Managing Director of Vivo Capital LLC, a healthcare focused investment firm, since October 2016 where he focuses on investments in life sciences companies. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, Inc. from April 2014 through October 2016. From January 2013 through December 2013, Dr. Aggarwal served as Managing Director of Investor Growth Capital. From August 2006 through December 2012, Dr. Aggarwal served as a General Partner at Panorama Capital, L.P., a venture capital fund. From March 2004 until August 2006, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co. Prior to joining JPMorgan Partners, LLC, Dr. Aggarwal focused on venture capital investments in biopharmaceutical and medical device companies at KBL Healthcare Ventures and Wasserstein Perrella & Co. Dr. Aggarwal previously served on the boards of directors of Hyperion Therapeutics, Inc. (acquired by Horizon Pharma) and Microlin Bio, Inc. Dr. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons, and his B.S. in Agricultural Economics from Cornell University. Our Board of Directors believes that Dr. Aggarwal should serve as a director based upon his medical background and his experience in the venture capital industry.

How old is Gaurav Aggarwal?

Gaurav Aggarwal is 47, he's been the Independent Director of Sierra Oncology Inc since 2019. There are 14 older and 2 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.

What's Gaurav Aggarwal's mailing address?

Gaurav's mailing address filed with the SEC is C/O GERON CORPORATION, 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY, CA, 94404.

Insiders trading at Sierra Oncology Inc

Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth e James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.

What does Sierra Oncology Inc do?

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Complete history of Gaurav Aggarwal stock trades at Geron e Sierra Oncology Inc

Sierra Oncology Inc executives and stock owners

Sierra Oncology Inc executives and other stock owners filed with the SEC include:

• Barbara Klencke,
  Chief Development Officer
• Mark Kowalski,
  Chief Medical Officer
• Sukhi Jagpal,
  Chief Financial Officer
• Dr. Stephen George Dilly M.B.B.S, Ph.D.,
  Pres, CEO & Director
• Dr. Barbara J. Klencke M.D.,
  Chief Medical Officer
• Dr. Mark M. Kowalski M.D., Ph.D.,
  Chief of Research & Early Devel.
• Robert Pelzer,
  Independent Chairman of the Board
• James Smith,
  Vice President Corporate Affairs
• Andrew Sinclair,
  Independent Director
• Josh Richardson,
  Independent Director
• Jeffrey Cooper,
  Independent Director
• Mona Ashiya,
  Independent Director
• Andrew Allen,
  Independent Director
• Gaurav Aggarwal,
  Independent Director
• Craig Collard,
  Director
• William Turner,
  Chief Regulatory and Technical Operations Officer
• Kevin Norrett,
  Chief Business Officer
• Christina Thomson,
  General Counsel
• Stephen Dilly,
  President, Chief Executive Officer, Director
• Kevin Norrett M.B.A., M.S.,
  Chief Bus. Officer
• William D. Turner,
  Chief Regulatory & Technical Operations Officer
• Christina Thomson J.D., M.S.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Sukhi Jagpal CA, CPA, CBV, MBA,
  Chief Financial Officer
• Daniel Estes,
  Director
• James N Topper,
  Director
• Nicholas Glover,
  CEO and President
• Nicole Onetto,
  Director
• Tran Nguyen,
  Director
• Donald R Parfet,
  Director
• Angie You,
  Chief Bus. & Strat. Officer
• Capital Partners Iii, Llc L...,
  
• Christian Hassig,
  Chief Scientific Officer
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llcorbimed Capital...,
  
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llc Orbi Med Capit...,
  
• Georgia Erbez,
  Director
• Christy J. Oliger,
  Director
• Llp Abingworth,
  10% owner
• Mary Christina Thomson,
  General Counsel
• Advisors Llc Orbi Med Capit...,